Haemonetics Co. (NYSE:HAE) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group trimmed its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 894,539 shares of the medical instruments supplier's stock after selling 42,750 shares during the period. Schroder Investment Management Group owned about 1.78% of Haemonetics worth $69,846,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Cerity Partners LLC grew its stake in shares of Haemonetics by 31.1% during the 3rd quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock worth $712,000 after purchasing an additional 2,102 shares during the period. FMR LLC grew its position in Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after buying an additional 521,640 shares during the period. BNP Paribas Financial Markets increased its holdings in Haemonetics by 174.5% in the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock valued at $1,362,000 after buying an additional 10,774 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Haemonetics by 30.1% in the third quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier's stock worth $341,000 after acquiring an additional 982 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in shares of Haemonetics during the 3rd quarter worth about $623,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Haemonetics Price Performance

NYSE HAE traded down $1.42 during trading hours on Friday, hitting $60.80. 1,019,545 shares of the company's stock traded hands, compared to its average volume of 671,984. The company has a market capitalization of $3.05 billion, a PE ratio of 23.94, a PEG ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. Haemonetics Co. has a 52-week low of $58.80 and a 52-week high of $97.97. The firm's 50-day moving average is $65.01 and its 200-day moving average is $74.25.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Needham & Company LLC cut their price target on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. JMP Securities cut their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.